Proteogenomic Characterization of Endometrial Carcinoma
Yongchao Dou,Emily A Kawaler,Daniel Cui Zhou,Marina A Gritsenko,Chen Huang,Lili Blumenberg,Alla Karpova,Vladislav A Petyuk,Sara R Savage,Shankha Satpathy,Wenke Liu,Yige Wu,Chia-Feng Tsai,Bo Wen,Zhi Li,Song Cao,Jamie Moon,Zhiao Shi,MacIntosh Cornwell,Matthew A Wyczalkowski,Rosalie K Chu,Suhas Vasaikar,Hua Zhou,Qingsong Gao,Ronald J Moore,Kai Li,Sunantha Sethuraman,Matthew E Monroe,Rui Zhao,David Heiman,Karsten Krug,Karl Clauser,Ramani Kothadia,Yosef Maruvka,Alexander R Pico,Amanda E Oliphant,Emily L Hoskins,Samuel L Pugh,Sean J I Beecroft,David W Adams,Jonathan C Jarman,Andy Kong,Hui-Yin Chang,Boris Reva,Yuxing Liao,Dmitry Rykunov,Antonio Colaprico,Xi Steven Chen,Andrzej Czekański,Marcin Jędryka,Rafał Matkowski,Maciej Wiznerowicz,Tara Hiltke,Emily Boja,Christopher R Kinsinger,Mehdi Mesri,Ana I Robles,Henry Rodriguez,David Mutch,Katherine Fuh,Matthew J Ellis,Deborah DeLair,Mathangi Thiagarajan,D R Mani,Gad Getz,Michael Noble,Alexey I Nesvizhskii,Pei Wang,Matthew L Anderson,Douglas A Levine,Richard D Smith,Samuel H Payne,Kelly V Ruggles,Karin D Rodland,Li Ding,Bing Zhang,Tao Liu,David Fenyö,Clinical Proteomic Tumor Analysis Consortium,Anupriya Agarwal,Meenakshi Anurag,Dmitry Avtonomov,Chet Birger,Michael J Birrer,Simina M Boca,William E Bocik,Uma Borate,Melissa Borucki,Meghan C Burke,Shuang Cai,Anna Calinawan,Steven A Carr,Sonya Carter,Patricia Castro,Sandra Cerda,Michelle Chaikin,Daniel W Chan,Doug Chan,Alyssa Charamut,Feng Chen,Jin Chen,Lijun Chen,Lin S Chen,David Chesla,Milan G Chheda,Arul M Chinnaiyan,Shrabanti Chowdhury,Marcin P Cieslik,David J Clark,Sandra Cottingham,Houston Culpepper,Jacob Day,Stephanie De Young,Emek Demir,Saravana Mohan Dhanasekaran,Rajiv Dhir,Marcin J Domagalski,Peter Dottino,Brian Druker,Elizabeth Duffy,Maureen Dyer,Nathan J Edwards,Robert Edwards,Kim Elburn,Jayson B Field,Alicia Francis,Stacey Gabriel,Yifat Geffen,Daniel Geiszler,Michael A Gillette,Andrew K Godwin,Pamela Grady,Linda Hannick,Pushpa Hariharan,Sue Hilsenbeck,Barbara Hindenach,Katherine A Hoadley,Runyu Hong,Galen Hostetter,James J Hsieh,Yingwei Hu,Michael M Ittmann,Eric Jaehnig,Scott D Jewell,Jiayi Ji,Corbin D Jones,Renee Karabon,Karen A Ketchum,Munziba Khan,Beom-Jun Kim,Azra Krek,Tanya Krubit,Chandan Kumar-Sinha,Felipe D Leprevost,Michael Lewis,Qing Kay Li,Yize Li,Hongwei Liu,Jan Lubinski,Weiping Ma,Rashna Madan,Ewa Malc,Anna Malovannaya,Sailaja Mareedu,Sanford P Markey,Annette Marrero-Oliveras,John Martignetti,Jason McDermott,Peter B McGarvey,John McGee,Piotr Mieczkowski,Francesmary Modugno,Rebecca Montgomery,Chelsea J Newton,Gilbert S Omenn,Amanda G Paulovich,Amy M Perou,Francesca Petralia,Paul Piehowski,Larisa Polonskaya,Liqun Qi,Shannon Richey,Karna Robinson,Nancy Roche,Daniel C Rohrer,Eric E Schadt,Michael Schnaubelt,Yan Shi,Tara Skelly,Lori J Sokoll,Xiaoyu Song,Stephen E Stein,James Suh,Donghui Tan,Darlene Tansil,Guo Ci Teo,Ratna R Thangudu,Cristina Tognon,Elie Traer,Jeffrey Tyner,Ki Sung Um,Dana R Valley,Negin Vatanian,Pankaj Vats,Uma Velvulou,Michael Vernon,Liang-Bo Wang,Ying Wang,Alex Webster,Thomas Westbrook,David Wheeler,Jeffrey R Whiteaker,George D Wilson,Yuriy Zakhartsev,Robert Zelt,Hui Zhang,Yuping Zhang,Zhen Zhang,Grace Zhao
DOI: https://doi.org/10.1016/j.cell.2020.01.026
IF: 64.5
2020-02-20
Cell
Abstract:We undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences of perturbations to the p53 and Wnt/β-catenin pathways, identified a potential role for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic markers of clinical and genomic tumor subgroups, including relationships to known druggable pathways. An extensive genome-wide acetylation survey yielded insights into regulatory mechanisms linking Wnt signaling and histone acetylation. We also characterized aspects of the tumor immune landscape, including immunogenic alterations, neoantigens, common cancer/testis antigens, and the immune microenvironment, all of which can inform immunotherapy decisions. Collectively, our multi-omic analyses provide a valuable resource for researchers and clinicians, identify new molecular associations of potential mechanistic significance in the development of endometrial cancers, and suggest novel approaches for identifying potential therapeutic targets.